FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) For Giant Cell Arteritis
FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) For Giant Cell Arteritis There have been no new therapies for GCA in more than 50 years Breakthrough Therapy Designation was granted to Actemra for the treatment of GCA by the FDA in 2016 January 24, 2017 Genentech, a member of the [..]